Biphasic magnetic nanoparticles-nanovesicle hybrids for chemotherapy and self-controlled hyperthermia

Nanomedicine

Volumn 9, Issue 7, 2014, Pages 955-970

  Gogoi, Manashjit ^a   Sarma, Haladhar D ^b   Bahadur, Dhirendra ^a   Banerjee, Rinti ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^b BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

biphasic suspension; cancer; chemotherapy; magnetic nanovesicle; self controlled hyperthermia

Indexed keywords

CHOLESTEROL; DEXTRAN; IRON; LANTHANUM; MAGNETIC NANOPARTICLE; MAGNETIC NANOVESICLE; PACLITAXEL; STRONTIUM; UNCLASSIFIED DRUG; MAGNETITE; MAGNETITE NANOPARTICLE;

ALTERNATING CURRENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RELEASE; FEMALE; HEATING; HUMAN; HUMAN CELL; HYPERTHERMIA; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MAGNETIC FIELD; MOUSE; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; SUSPENSION; TEMPERATURE; CELL SURVIVAL; CHEMISTRY; HYPERTHERMIC THERAPY; IC50; MCF 7 CELL LINE; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

CELL SURVIVAL; DEXTRANS; FERROSOFERRIC OXIDE; HUMANS; HYPERTHERMIA, INDUCED; INHIBITORY CONCENTRATION 50; MAGNETITE NANOPARTICLES; MCF-7 CELLS; MICROSCOPY, ELECTRON, TRANSMISSION; PACLITAXEL;

EID: 84903843978     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.90     Document Type: Article

References (48)

1. Jordan A, Scholz R, Maier-Hauff K et al. Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia. J. Magn. Magn. Mater. 225(1-2), 118-126 (2001). (Pubitemid 32335284)
2. Schneiderman MH, Hofer KG, Schneiderman GS. Targets for radiation-induced cell death: when DNA damage doesn't kill. Radiat. Res. 155(4), 529-535 (2001). (Pubitemid 32260250)
3. Gogoi M, Jaiswal MK, Banerjee R, Bahadur D. Magnetic nanovesicles and hydrogels towards cancer therapy. In: Magnetic Nanoparticles from Fabrication to Clinical Applications. Thanh NTK (Ed.). CRC Press, London, UK, 479-498 (2011).
4. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer. Sci. 94(12), 1021-1028 (2003). (Pubitemid 38035514)
5. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005). (Pubitemid 40093472)
6. Bouzin C, Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist. Updat. 10(3), 109-120 (2007). (Pubitemid 47031051)
7. Streffer C. Molecular and cellular mechanisms of hyperthermia. In: Thermoradiotherapy and Thermochemotherapy. Seegenschimicdt MH, Fessenden P, Vernon CC (Eds). Springer Verlag, Berlin, Germany, 47-74 (1995).
8. Hildebrandt B, Wust P, Ahlers O et al. The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol. Hematol. 43(1), 33-56 (2002). (Pubitemid 34722786)
9. Kong G, Dewhirst MW. Hyperthermia and nanovesicles. Int. J. Hyperthermia 15(5), 345-370 (1999).
10. Kong G, Braun RD, Dewhirst MW. Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res. 61, 3027-3032 (2001). (Pubitemid 32691950)
11. Yanase M, Shinkai M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using magnetite cationic nanovesicles: an in vivo study. Jpn J. Cancer Res. 89, 463-469 (1998). (Pubitemid 28226929)
12. Ito A, Tanaka K, Honda H, Abe S, Yamaguchi H, Kobayashi T. Complete regression of mouse mammary carcinoma with a size greater than 15 mm by frequent repeated hyperthermia using magnetite nanoparticles. J. Biosci. Bioeng. 96(4), 364-369 (2003).
13. Pradhan P, Giri J, Rieken F et al. Targeted temperature sensitive magnetic nanovesicles for thermo-chemotherapy. J. Control. Release 142(1), 108-121 (2010).
14. Dilnawaz F, Singh A, Mohanty C, Sahoo SK. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31(13), 3694-3706 (2010).
15. Kulshrestha P, Gogoi M, Bahadur D, Banerjee R. In vitro application of paclitaxel loaded magnetonanovesicles for combined chemotherapy and hyperthermia. Colloid. Surf. B Biointerfaces 96, 1-7 (2012).
16. Zhang J, Misra RDK. Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: core-shell nanoparticle carrier and drug release response. Acta Biomater. 3, 838-850 (2007).
17. Shido Y, Nishida Y, Suzuki Y, Kobayashi T, Ishiguro N. Targeted hyperthermia using magnetite cationic nanovesicles and an alternating magnetic field in a mouse osteosarcoma model. J. Bone Joint Surg. Br. 92(4), 580-585 (2010).
18. Vasseur S, Duguet E, Portier J et al. Lanthanum manganese perovskite nanoparticles as possible in vivo mediators for magnetic hyperthermia. J. Magn. Magn. Mater. 302(2), 315-320 (2006).
19. Liangruksa M, Ganguly R, Puri IK. Parametric investigation of heating due to magnetic fluid hyperthermia in a tumor with blood perfusion. J. Magn. Magn. Mater. 323(6), 708-716 (2011).
20. Kuznetsov AA, Leontiev VG, Brukvin VA et al. Local radiofrequency-induced hyperthermia using CuNi nanoparticles with therapeutically suitable Curie temperature. J. Magn. Magn. Mater. 311(1), 197-203 (2007).
21. Pollert E, Knízek K, Marysko M, Kaspar P, Vasseur S, Duguet E. New Tc-tuned magnetic nanoparticles for self-controlled hyperthermia. J. Magn. Magn. Mater. 316 (2), 122-125 (2007).
22. Shlyakhtin OA, Leontiev VG, Oh Y, Kuznetsov AA. New manganite-based mediators for self-controlled magnetic heating. Smart Mater. Struct. 16(5), N35-N39 (2007). (Pubitemid 351291566)
23. Prasad N, Rathinasamy K, Panda D, Bahadur D. Tc-tuned biocompatible suspension of La0.73Sr0.27MnO3 for magnetic hyperthermia. J. Biomed. Mater. Res. B Appl. Biomater. 85, 409-416 (2008).
24. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N. Engl. J. Med. 332, 1004-1014 (1995).
25. McMullen TPW, McElhaney RN. Differential scanning calorimetric studies of the interaction of cholesterol with distearoyl and dielaidoyl molecular species of phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine. Biochemistry 36, 4979-4986 (1997)
26. Prasad NK, Hardel L, Duguet E, Bahadur D. Magnetic hyperthermia with biphasic gel of La1-xSrxMnO3 and maghemite. J. Magn. Magn. Mater. 321, 1490-1492 (2009).
27. Shiigi SM, Slomich M. Heterologous antisera to mouse brain. In: Selected Methods in Cellular Immunology. Mishell BB, Shiigi MS (Eds). WH Freeman Co., CA, USA, 247-257 (1980).
28. Cullity BD, Graham CD. Introduction to Magnetic Materials (2nd Edition). John Wiley & Sons Inc., NJ, USA (2008).
29. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 1, 1112-1126 (2006).
30. Anand P, Huilgol N, Banerjee R. Effect of fluidizing agents on paclitaxel penetration in cervical cancerous monolayer membranes. J. Membr. Biol. 219, 83-91 (2007).
31. Zhang Y, Tang L, Sun L et al. A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomater. 6, 2045-2052 (2009).
32. Jin C, Bai L, Wu H, Tian F, Guo G. Radiosensitization of paclitaxel, etanidazole and paclitaxel+etanidazole nanoparticles on hypoxic human tumor cells in vitro. Biomaterials 28, 3724-3730 (2007). (Pubitemid 46855881)
33. Semple SC, Chonn A, Cullis PR. Influence of cholesterol on the association of plasma proteins wit liposomes. Biochemistry 35, 2521-2525 (1996). (Pubitemid 26098761)
34. Gabizon A, Chemla M, Tzemach D, Horowitz AT, Goren D. Nanovesicle longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J. Drug Targeting 3, 391-398 (1996).
35. Parr MJ, Masin D, Cullis PR, Bally MB. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating nanovesicles with poly(ethylene glycol). J. Pharmacol. Exp. Ther. 280, 1319-1327 (1997).
36. Mayer LD, Cullis PR, Bally MB. Designing therapeutically optimized liposomal anticancer delivery systems: lessons from conventional nanovesicles. In: Medical Applications of Nanovesicles. Lasic DD, Papahadjopoulos D (Eds). Elsevier, Amsterdam, The Netherlands, 231-257 (1998).
37. Hong RL, Huang CJ, Tseng YL et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice is surface coating with polyethylene glycol beneficial? Clin. Cancer Res. 5, 3645-3652 (1999).
38. Kohler N, Sun C, Fichtenholtz A, Gunn J, Fang C, Zhang M. Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery. Small 2, 785-792 (2006). (Pubitemid 43745151)
39. Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J. Microencapsul. 13, 245-255 (1996).
40. Arias JL, Ruiz MA, Gallardo V, Delgado AV. Tegafur loading and release properties of magnetite/poly(alkylcyanoacrylate) (core/shell) nanoparticles. J. Control. Release 125, 50-58 (2008).
41. Kim SY, Lee YM. Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(epsilon-caprolactone) as novel anticancer drug carriers. Biomaterials 22, 1697-1704 (2001). (Pubitemid 32564958)
42. Chattopadhyay P, Gupta RB. Supercritical CO2 based production of magnetically responsive micro- and nanoparticles for drug targeting. Ind. Eng. Chem. Res. 41, 6049-6058 (2002). (Pubitemid 35386756)
43. Zhu L, Ma J, Jia N, Zhao Y, Shen H. Chitosan-coated magnetic nanoparticles as carriers of 5-fluorouracil: preparation, characterization and cytotoxicity studies. Colloid. Surf. B Biointerface 68, 1-6 (2009).
44. Luo S, Zhang E, Su Y, Cheng T, Shi C. A review of NIR dyes in cancer targeting and imaging. Biomaterials 32, 7127-7138 (2011).
45. Links M, Brown R. Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev. Mol. Med. 1999, 1-21 (1999).
46. Krishna R, Mayer L. Applications of nanovesicle technology to overcome multidrug resistance in solid tumors. In: Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems (NATO ASI Series). Gregoriadis G, McCormack B (Eds). Plenum Press, NY, USA, 95-108 (1998).
47. Prasad NK, Rathinasamy K, Panda D, Bahadur D. Mechanism of cell death induced by magnetic hyperthermia with nanoparticles of g-MnxFe2-xO3 synthesized by a single step process. J. Mater. Chem. 17, 5042-5051 (2007).
48. Ito A, Fujioka M, Yoshida T et al. 4-S-cysteaminylphenol-loaded magnetite cationic nanovesicles for combination therapy of hyperthermia with chemotherapy against malignant melanoma. Cancer Sci. 98, 424-430 (2007).